Market Signal Briefing

NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Perrigo securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Perrigo. class action, go to https://rosenlegal.com/submit-form/?case_id=48085 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and or failed to disclose that: (1) the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance; (2) Perrigo needed to make substantial capital and operational expenditures above Perrigo’s outwardly stated cost estimates to remediate the infant formula business; (3) there were significant manufacturing deficiencies in the facility for Perrigo’s infant formula business; (4) as a result of the foregoing, Perrigo’s financial results, including earnings and cash flow, were overstated; and (5) as a result of the foregoing, defendants’ positive statements about Perrigo’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Perrigo class action, go to https://rosenlegal.com/submit-form/?case_id=48085 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Meta is developing new mixed reality glasses under the codename Phoenix, according to Business Insider — but their release date has been pushed back from the second half of 2026 to the first half of 2027.

The Facebook parent company already sells VR headsets and Ray-Ban smart glasses, but these glasses sound a bit different; their format factor would reportedly be similar to the Apple Vision Pro, with a puck-like power source.

BI says it’s seen memos from Meta executives announcing the delay, apparently after meetings in which CEO Mark Zuckerberg told them to take more time to make the business sustainable and deliver higher quality experiences.

The company’s metaverse leaders Gabriel Aul and Ryan Cairns reportedly wrote that the delay is “going to give us a lot more breathing room to get the details right.”

Bloomberg reported earlier this week that Meta plans to slash its metaverse budget by up to 30%.

NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Primo Water Corporation (NYSE: PRMW) between June 17, 2024 and November 8, 2024, both dates inclusive, and/or (ii) purchasers of common stock of Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 and November 6, 2025 (the “Class Period”), of the important January 12, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Primo Brands securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Primo Brands class action, go to https://rosenlegal.com/submit-form/?case_id=47890 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, Primo Brands formed following the November 8, 2024 merger between Primo Water and BlueTriton Brands, is a branded beverage company that offers beverage products across a variety of formats, channels, and price points. According to the lawsuit, throughout the Class Period, defendants misrepresented and failed to disclose key facts about the merger between Primo Water and BlueTriton Brands, including facts regarding the progress of the merger integration. Defendants issued a series of materially false and misleading statements that led investors to believe the merger would accelerate growth, generate transformative operational efficiencies, achieve meaningful synergies, and deliver strong financial results, and that the merger integration was proceeding “flawlessly.” When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Primo Brands class action, go to https://rosenlegal.com/submit-form/?case_id=47890 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

You'd likely be impressed with your gains, but the volatility could be hard to stomach.

Since Bitcoin became mainstream, there has been an influx of new cryptocurrencies. In most cases, these cryptocurrencies have little to no tangible use for the public and are nothing more than pump-and-dump schemes for their creators and insiders.

However, a few non-Bitcoin cryptocurrencies have gained traction and present real-world use cases, with XRP (XRP 0.30%) being one of them. At the time of writing, XRP's price sits at $2.20. That's up 465% in the past three years, meaning a $1,000 investment made then would be worth around $5,650 today.

Image source: Getty Images.

So what exactly does XRP do?
XRP was created with the goal of making cross-border transactions faster and cheaper. Right now, most cross-border transactions are costly because they involve multiple financial institutions, including local banks and correspondent banks. The cost to send money can be as high as 7% in some cases. By removing intermediaries, XRP can make these transfers virtually instantly for fractions of a cent.

Today's Change

(

-0.30

%) $

-0.01

Current Price

$

2.03

XRP's use case hasn't caught on in the mainstream, but the projected growth of the cross-border payments market has kept optimism high among XRP enthusiasts.

Like any cryptocurrency, XRP's volatility makes it challenging to store value. However, it stands out among cryptocurrencies for its mission and real-world use case.

Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bitcoin and XRP. The Motley Fool has a disclosure policy.

As of December 2025, Bitcoin is valued at $89,618, bringing its total market capitalization to $1.78 trillion. The leading cryptocurrency has experienced a 24-hour trading volume of $45.76 billion, with its price fluctuating narrowly between $88,420 and $91,290. This range-bound movement indicates a period of market indecision where participants are neither ready to trigger a massive sell-off nor confident enough to push the price significantly higher.

The current price stability of Bitcoin is marked by a lack of clear direction, reflecting the ongoing tug-of-war between optimistic bulls and cautious bears. This stalemate hints at a larger global economic context where investors weigh potential risks against prospective returns. Recently, Bitcoin has witnessed significant volatility, influenced by macroeconomic factors, including inflation and interest rate changes. These elements have forced traders to adopt a more nuanced approach rather than reacting with panic or exuberance.

Historically, Bitcoin has been volatile, with dramatic price swings often linked to regulatory news, technological developments, or shifts in demand and supply. In previous years, major announcements such as the introduction of futures trading, or regulatory clampdowns in key markets like China, have sent ripples through the cryptocurrency space. As such, today’s steadiness might suggest a maturing market where factors other than speculation are gaining influence.

Despite this maturity, Bitcoin’s price is still susceptible to external shocks. For instance, changes in U.S. monetary policy or geopolitical tensions could alter investor sentiment abruptly. The Federal Reserve’s decisions on interest rates have historically impacted risky assets, including cryptocurrencies. With a strong U.S. dollar, for example, Bitcoin might struggle to gain traction as investors seek safer, more stable returns. On the other hand, a depreciating dollar could bolster Bitcoin as an alternative store of value.

Adding complexity to the current scenario is the global regulatory environment. More nations are adopting frameworks to regulate cryptocurrencies, attempting to harness the technology’s potential while mitigating associated risks. The European Union’s recent advancements in cryptocurrency regulation aim for comprehensive oversight, which could impact Bitcoin’s price stability. Simultaneously, countries like El Salvador have embraced Bitcoin as legal tender, creating a unique dynamic that could influence market behavior.

While the adoption of Bitcoin and other cryptocurrencies has grown, skepticism remains. Critics often point to environmental concerns associated with Bitcoin mining, which demands substantial energy resources. Despite efforts to shift towards renewable energy, this remains a contentious issue, potentially influencing regulatory actions and investor sentiment negatively.

Moreover, the increasing competition from other cryptocurrencies poses another challenge. Ethereum, with its smart contract capabilities, and newer entrants focusing on scalability and efficiency, offer alternatives that could divert interest away from Bitcoin. The growing ecosystem of decentralized finance (DeFi) and non-fungible tokens (NFTs) also showcases innovation beyond Bitcoin’s original scope, prompting investors to diversify their portfolios.

In parallel, the emergence of central bank digital currencies (CBDCs) represents another frontier. Countries like China are pioneering digital yuan initiatives, which could redefine how digital transactions occur, potentially impacting Bitcoin’s role. If CBDCs gain widespread acceptance, they could offer a state-backed alternative that challenges Bitcoin’s appeal as a transactional medium.

Despite these challenges, Bitcoin’s foundational role in the cryptocurrency ecosystem remains unshaken. Institutional adoption continues to rise, with financial giants and companies integrating Bitcoin into their investment strategies. This institutional interest not only validates Bitcoin’s potential but also infuses the market with a layer of stability that retail investors alone could not achieve.

However, the journey forward is fraught with uncertainties. A significant risk is the potential for technological disruption. Advances in quantum computing, for instance, could, in theory, undermine Bitcoin’s cryptographic security, posing a daunting challenge. Although current assessments suggest such threats are still distant, the crypto community must remain vigilant.

Another risk involves market manipulation. Given its decentralized nature, Bitcoin is susceptible to price manipulation by large holders, known as “whales,” who can influence market trends and sentiment with substantial transactions. Such dynamics could lead to price distortions that might mislead less experienced investors.

In conclusion, while Bitcoin’s price has stabilized within a narrow range, signaling caution rather than capitulation, the broader landscape suggests a mix of opportunities and obstacles. The interplay of regulatory developments, technological innovations, and geopolitical factors will continue to shape its trajectory. As Bitcoin navigates through these complex waters, its ability to maintain relevance depends on adaptability and resilience against emerging challenges in the rapidly evolving digital asset landscape.

Post Views: 12

Texas has officially become the first U.S. state to acquire Bitcoin for a government strategic reserve, purchasing $5 million worth of the digital asset on November 20 at roughly $87,000 per BTC. The move was confirmed by Lee Bratcher, president of the Texas Blockchain Council, who said the initial allocation was executed through BlackRock’s iShares Bitcoin Trust (IBIT) while the state finalizes its self-custody framework.

The purchase marks a significant milestone in state-level adoption of Bitcoin as a reserve asset. Texas lawmakers had explored creating a strategic Bitcoin reserve as early as last year, emphasizing that it would not rely on taxpayer funds. The initiative became law in June when the governor formally established the Texas Strategic Bitcoin Reserve.

Bratcher, who played a key role in crafting and advancing the legislation through the state Senate, noted that self-custody remains the long-term goal. “Texas will eventually self-custody bitcoin,” he said, “but while that RFP process takes place, this initial allocation was made with BlackRock’s IBIT ETF.”

As president and founder of the Texas Blockchain Council, an industry association representing more than 100 companies, Bratcher has been a central advocate for positioning Texas as a national leader in Bitcoin and blockchain innovation. The state’s inaugural purchase signals what advocates view as a rising trend of governmental interest in digital assets as part of future financial strategy.

On a recent Friday, as Bitcoin’s value dipped below the significant $90,000 mark, a previously inactive wallet from 2012 suddenly became active. This wallet, untouched for over 13 years, transferred 1,000 BTC, which at current valuations equates to roughly $89.4 million. This move occurred at block height 926566, and shortly afterward, another wallet mirrored this action by transferring another 1,000 BTC.

The awakening of these Bitcoin wallets, often referred to as “sleeping” wallets due to their prolonged inactivity, has sparked interest and speculation within the cryptocurrency community. These wallets, which have remained untouched for long periods, represent substantial sums of money. In this case, the activation involved Bitcoin that had not moved since the early days of the cryptocurrency, highlighting both the enduring potential of Bitcoin and the trust that holders have had in its value over time.

Bitcoin, launched in 2009, has experienced a volatile journey, with its price experiencing dramatic rises and falls. Despite its fluctuations, Bitcoin has seen a general upward trend, bolstering its reputation as a potential store of value comparable to gold. The recent movement of these large sums of Bitcoin raises questions about the motivations behind these transactions. It could suggest a strategic decision by the holders to capitalize on market conditions or to diversify their holdings.

Historically, the movement of dormant Bitcoin can lead to speculation about market impacts. In some cases, significant transactions have influenced short-term price swings due to the sudden increase in available supply. Additionally, such activities can lead to discussions about the security and anonymity of Bitcoin transactions. Despite the digital currency’s pseudonymous nature, large movements attract attention and can sometimes be traced to specific entities or individuals.

The resurgence of these wallets is not unprecedented but is noteworthy due to the substantial value they represent. In the context of Bitcoin’s history, similar occurrences have been observed when prices reach new highs or lows, suggesting that some long-term holders might choose these moments to realize profits or reallocate assets.

The significance of these movements extends beyond mere financial interest; they also highlight the technological resilience of Bitcoin. The cryptocurrency’s underlying blockchain technology ensures that these transactions, even when dormant for years, are executed securely and efficiently. The blockchain’s decentralized nature means that no central authority can interfere with these transactions, reinforcing the trust in the systemic integrity of Bitcoin.

While such movements can stimulate the market and generate interest, they also carry risks. Large movements of Bitcoin can lead to price volatility, which, while beneficial for traders, can pose risks for less experienced investors or those holding Bitcoin as a long-term store of value. Moreover, there’s the potential for these actions to influence regulatory discussions. As governments worldwide continue to refine their approaches to cryptocurrency regulation, significant movements can either prompt stricter policies or encourage more open dialogues about the role of digital currencies in the global financial system.

Regulatory landscapes have evolved significantly since Bitcoin’s inception. In its early days, Bitcoin operated in a largely unregulated space, perceived by many governments as a fringe technology. However, as its adoption has grown, so too has the regulatory framework surrounding it. Countries like the United States, the European Union, and others have developed detailed regulations addressing cryptocurrency exchanges, trading practices, and taxation. These developments underscore the importance of balancing innovation with consumer protection and financial stability.

Comparatively, other nations like El Salvador have taken adventurous steps, even legalizing Bitcoin as legal tender. This move is part of a broader strategy to increase financial inclusion and integrate more citizens into the global economy. The interplay between regulatory environments and cryptocurrency activities remains a critical area for future development.

Despite these advances, challenges persist. Cybersecurity remains a primary concern for both individuals and exchanges, as the history of Bitcoin is marred with high-profile hacks and thefts. Enhanced security measures and user education are vital to safeguarding assets in the digital age. Additionally, the environmental impact of Bitcoin mining continues to provoke debate. The energy-intensive nature of mining has led to criticisms about sustainability, prompting some regions to consider restrictions or bans on mining activities.

As Bitcoin continues to develop, its ability to adapt to changing market conditions and regulatory landscapes will be crucial. The reactivation of long-dormant wallets underscores the confidence some long-term investors have in Bitcoin’s enduring value. However, this confidence is tempered by the potential for volatility and regulatory challenges.

Ultimately, the reactivation of these wallets is a testament to Bitcoin’s lasting impact on the financial landscape. As the digital currency continues to evolve, it remains a focal point for discussions on decentralization, financial innovation, and the future of money. Whether as a speculative asset or a potential hedge against inflation, Bitcoin’s role in the global economy is set to remain significant, with these recent transactions serving as a reminder of its dynamic and ever-changing nature.

In conclusion, the movement of dormant Bitcoins illustrates both the opportunities and complexities inherent in the cryptocurrency market. As Bitcoin navigates its path forward, the lessons learned from these movements will shape the future of digital currencies and their place in the world economy. The next chapter in Bitcoin’s story will likely continue to challenge traditional financial paradigms, offering novel opportunities and posing new questions for investors, regulators, and technologists alike.

Post Views: 15

Polytrade has taken a pivotal role in shaping the future of real estate tokenization by becoming the Lead Development Anchor for the Integra Consortium, a move revealed on December 6, 2025. This strategic alliance positions Polytrade at the forefront of developing a blockchain specifically designed for the global real-estate market. The collaboration aims to address the unique challenges associated with real-world asset (RWA) tokenization by leveraging Polytrade’s extensive experience and technological innovations.

Historically, real estate has been a cornerstone of wealth creation and investment, but its integration into blockchain technology has been fraught with complexities. Traditional blockchains have struggled to meet the stringent requirements of data management, compliance, and valuation essential for institutional real estate markets. Since 2021, Polytrade has been a leader in bridging this gap, establishing a vibrant ecosystem that includes issuers, liquidity providers, and enterprise partners. This rich tapestry of relationships highlighted the need for a blockchain tailored to the regulated nature of real estate assets.

Polytrade’s journey over the past five years has been marked by significant collaborations with major banks, funds, and multinational enterprises. Through these partnerships, including a notable association with Mastercard, Polytrade has gathered insights that underscore the necessity for a specialized blockchain environment. Such an environment is now being realized with Integra, a blockchain purposefully built to embed asset information, compliance proofs, and market applications seamlessly within its architecture.

Integra’s vision is ambitious. By creating a vertically integrated ecosystem, it seeks to streamline the management and exchange of tokenized real estate assets at scale. Announced in a whitepaper on November 28, Integra’s comprehensive approach includes developing native applications and a stablecoin alongside the blockchain infrastructure. This model not only promises efficiency but also introduces new revenue streams through stablecoin yield and native decentralized applications (DApps) fees, differentiating it from other Layer 1 solutions that primarily rely on gas and transaction fees.

The consortium backing Integra is formidable, comprising major real estate asset managers such as Nitya Capital and technology innovators like Digishares. This collaboration ensures that Integra starts with a solid foundation, capable of handling substantial transactions, including hundreds of millions in rent, sales, and exits from its consortium members. Such scale is poised to redefine what an Asset-Specific Layer 1 (L1) blockchain can achieve in the marketplace.

Polytrade’s role extends beyond just technical development. With a robust distribution network and a mature RWA marketplace already in place, Polytrade is set to accelerate the adoption and integration of Integra’s blockchain. By facilitating the onboarding of institutional partners and managing asset flows, Polytrade enhances Integra’s value proposition, potentially setting a new standard for blockchain-enabled real estate operations.

In recognition of its community, Polytrade has announced that holders of its $TRADE token will receive an allocation of Integra’s native token, $IRL. This gesture underscores Polytrade’s commitment to its base as it transitions to this new venture. While details of the token allocation are still pending, the promise of participation in Integra’s future underlines the strategic alignment between the two entities.

The implications of this partnership are far-reaching. By merging Polytrade’s expertise with Integra’s specialized infrastructure, the consortium aims to transform global real-estate markets. This collaboration is not merely about technological advancement but represents a broader ambition to redefine how real estate transactions are conducted on a global scale.

Despite the optimism surrounding this initiative, it is not without risks. The integration of traditional real estate markets with blockchain technology poses significant regulatory challenges. Different jurisdictions have varying legal frameworks governing digital assets, which could complicate the rollout of such a system. Furthermore, the dependence on blockchain stability and cybersecurity presents ongoing risks that must be managed to maintain trust among institutional investors and regulators.

The Integra Consortium represents a significant step forward in the evolution of blockchain technology tailored to real-world applications. By harnessing Polytrade’s institutional knowledge and technological prowess, the consortium is poised to pioneer a new era in real estate asset management. As the blockchain landscape continues to evolve, such collaborations will be crucial in defining and mainstreaming innovative solutions that bridge traditional and digital asset markets.

In conclusion, the partnership between Polytrade and Integra is a testament to the transformative potential of blockchain technology in real estate. By addressing the specific needs of this market, the consortium not only positions itself as a leader in asset tokenization but also sets the stage for broader adoption and integration of blockchain solutions across industries. As the world increasingly moves towards digital transformation, initiatives like this are likely to pave the way for more secure, efficient, and accessible asset management systems.

Post Views: 8

Terraform Labs founder Do Kwon should serve at least 12 years behind bars for his role in the spectacular $40 billion implosion of the Terra ecosystem, U.S. federal prosecutors said on Thursday.

While Kwon’s team recently requested a 5-year sentence, U.S. officials contended that the massive scope of his crimes cries out for this lengthy prison sentence to discourage any future similar behavior.

Though Do Kwon faced up to 25 years in federal prison for his crimes, prosecutors agreed in August that they would push for up to 12 years as part of a plea deal reached with the ex-crypto mogul, where he pleaded guilty to conspiracy to commit fraud and wire fraud. 

In a sentencing submission filed on Thursday to the U.S. District Judge Paul Engelmayer for the Southern District of New York, DOJ attorneys argued that Kwon deserves a harsh sentence to avoid “unwarranted sentencing disparities” with other, similar cases — namely, that of FTX founder Sam Bankman-Fried.

In a 2023 jury trial, Bankman-Fried was convicted on seven counts of fraud and conspiracy for his role in the collapse of his $32 billion crypto empire. A judge later sentenced the former billionaire crypto wunderkind to 25 years in prison. 

Advertisement
 

“Judge Kaplan imposed a sentence of 25 years on Bankman-Fried, who, like Kwon, perpetrated a fraud of staggering proportions in his twenties and then attributed his brazen criminal conduct in part to youth and inexperience,” the prosecutors postulated.

The prosecutors also slammed Kwon’s legal team for claiming the Terra founder should receive a “far shorter sentence” than Celsius founder Alex Mashinsky, who was sentenced to 12 years in prison earlier this year for multi-billion-dollar fraud.

The Terra-Luna Implosion
Kwon, a 34-year-old South Korean citizen, found himself at the heart of a global financial implosion in 2022 when two cryptocurrencies he created, the algorithmic stablecoin UST and its sister token Luna, quickly crashed to zero, wiping out over $40 billion in investor money and triggering a cascading crisis in the cryptocurrency market. 

The resulting contagion event led to the downfall of several crypto entities in 2022, including FTX. Prosecutors claim Kwon misled investors about the risks and stability associated with the tokens. 

“Kwon deprived UST and Terra purchasers of the ability to make fully informed decisions about their purchases, and artificially inflated the value of Terraform’s cryptocurrencies, which directly enriched and raised Kwon’s profile,” they wrote in the filing.

The former Terraform boss fled the chaos, only to be arrested in Montenegro in 2023 while attempting to fly to Dubai with a forged passport. He was deported to New York earlier this year after an extremely lengthy jurisdictional contest.

“Kwon’s misconduct, the consequences of his crime, and his reaction to the discovery of his scheme all warrant a substantial prison term,” prosecutors noted. “Indeed, the circumstances of the offense, standing alone, would weigh strongly in favor of a maximum sentence.”

Kwon will be sentenced in Manhattan on December 11.

Ethereum, despite its recent woes, has the potential to rise to as high as $6800 according to a recent RSI analysis by an influencer on X (formerly Twitter). The second-largest cryptocurrency by market capitalization is currently trading right around the $3100 price level as the bulls try to chalk out a new strategy going into 2026. Ethereum has also enacted the latest Fusaka upgrade on its blockchain, a bold new initiative for scaling the legacy decentralized network.

Ethereum to Appreciate to $4300, Potential to Reach $6800
Skyodelic, the analyst in question, has recently been upbeat about Ethereum because of a bullish trend emerging from deep within the current bearish setup. He tweeted:

“$ETH looks ready to push much higher

In the last 5 years every single time the 1D RSI has gone from overbought, down to oversold, and then broken the trend(green circle)…

It has pumped a minimum of 45%.

Advertisement
 

That takes us to $4,300.

That is just the minimum, worst case scenario this is a bear market etc

The average is 111%…. Which would take us to $6,800.

Basically, whenever $ETH goes from overbought to oversold, and the breaks the downtrend…

It’s pushes very nicely.

Only one out of those 5 scenarios did $ETH double bottom after the break of trend… the other 4 times the bottom was in.

It broke that downtrend today quite convincingly.”

The tweet ended with graph:

Image Source: X
The analyst has identified key RSI trends from the last 3.5 years that predict a major price rebound is on its way. The focus is on the decisive breakout from the downward oversold territory that has dominated the market since the October 11 crash, forcing the larger crypto market on its back foot. 

Ethereum, as the graph indicates, has massive upside potential because of its successful rebound from lower RSI levels, which showed the digital currency was struggling in deep bearish territory below 30, hardly a week ago. Now, the situation has changed somewhat with the RSI recovering to 50 and the index feeling relatively safe around the $3.1k valuation.

A textbook reaction to this pattern would result in the premier programmable cryptocurrency rising to $4.3k, a figure which has been attributed as the “minimum worst case scenario”. In the best-case scenario, ETH could rise to $6800, representing a 111% price appreciation from current levels, as we see a clear shift from oversold to neutral RSI.

The Future
The future is tricky to predict, but in this case, the changeover from the oversold to neutral RSI territory is an important one that cannot be ignored by traders however, if we have already kick-started the next iteration of the bear market, which some analysts fear, low RSI levels mean nothing, as in such a scenario, the cryptocurrency can remain in oversold territory for long periods of time. 

The remaining days of December will be crucial in determining the future course of action for Ethereum.

The recent drop in Bitcoin dominance is pointing towards a major altseason, according to one popular analyst. This could be a major development for crypto traders, as both Bitcoin and altcoins are currently reeling from sustained attacks by bearish forces that have resulted in the overall digital currency market losing more than $1 trillion in valuation since the start of October.

Falling Bitcoin Dominance to Trigger Major Altseason?
Merlijn the Trader, a popular crypto analyst on X (formerly Twitter), argues for a major altcoin boom following a Bitcoin dominance peak during this cycle. He tweeted:

“BITCOIN DOMINANCE: THE CRASH SIGNAL IS BACK.

2017: Dominance topped. Altseason. Rugpull

2021: Same setup. Same result

Advertisement
 

2025: History repeats?

This signal has never missed.

BTC.D peaks. Alts explode. Then the floor disappears.

The clock is ticking.

Don’t get trapped”

Image Source: X
According to this analyst, Bitcoin dominance peaked above 65% earlier this year and has been sliding ever since. It is trading just south of the 60% share at press time. According to the analyst, the only outcome of this major development is a full-blown altseason, followed by a major rug pull that will bring altcoins crashing down.

Historical confirms this developing pattern: BTC.D fell from 65% to 35% in early 2018 after the 2017 peak, and from 70% to 40% in mid-2021, enabling altseason gains of 10x+ before 80%+ drawdowns in alt markets. The 80%+ loss doesn’t scare altcoin investors because they have been down this road before and are prepared to deal with it.

Traders Keep Their Fingers Crossed
Altcoin holders are optimistic about a possible altseason because it will open up the market considerably and pour a lot of capital into the system. Currently, the larger crypto market, especially the altcoin scene, is quite dead and trending largely downward. There are growing fears that we won’t see a major altcoin boom this time around, which could end the 4-year crypto cycle as we know it.

The fears are well-placed because this is the first time since 2017 that Bitcoin’s new ATHs have failed to trigger an altseason in the year following a halving. Virtually all of the top altcoins are yet to record a new ATH (apart from ETH and BNB), let alone go on a bullish frenzy. 

Further complications have arisen from the manner in which BTC’s dominance has declined so far. Previously, altcoins boosted their share by rallying hard against the premier digital currency, especially the top lot like ETH, XRP, and DOGE. This year, they have been reduced to playing catch-up with BTC and haven’t given a single indication that they aim to follow suit with an altseason. So, the doubts are very much around as well, and the incoming few months are expected to be crucial in determining the future of altseasons and their place in the crypto market, which has been taken for granted. 

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitcoin’s price action has been grossly dramatic throughout the year. After reaching its current all-time-high price of $126,000 in early October, the world’s leading cryptocurrency saw a rapid flip to the downside. Since reaching its October high, Bitcoin spiraled to as low as $80,500, a more than 15% negative deviation in reviewing year on year growth. 

As the market sentiment thus ostensibly leans bearish, an on-chain analysis has recently been published, proffering reasons to believe that the negative sentiment among investors could be growing stronger.

$91,000 Max Pain Point Breached After Friday Options Expiry
In a QuickTake post on CryptoQuant, crypto pundit GugaOnChain brings to light the expiry of about $3.4 billion in Bitcoin options. This expiration event, which took place on Friday, 5th December, is one that typically triggers a “gravitational force” which attracts price to itself. By extension, price tends to move towards a specific price level referred to as the Maximum Pain Point, where option buyers incur the greatest losses, and sellers realize the most profits.

Source: CryptoQuant
In this scenario, the Maximum Pain Point stood at approximately $91,000. As such, the Bitcoin price saw a rapid decline towards this mark. However, by the end of the session, Bitcoin had already slipped beneath its “gravitational force,” reaching as low as $89,500, and entering a range that amplified its buyers’ losses, while also maximizing its sellers’ (market makers) gains.

Negative Funding Rate Further Strengthens Bearish Narrative
GugaOnChain also references readings from the Bitcoin: Funding Rates metric, which tracks the average funding rate across all major perpetual futures exchanges. As the analyst explains, this metric is useful in reading the prevalent market sentiment. For example, negative Funding Rates, such as the current reading of -0.001206, typically indicate the willingness of short traders to pay the longs for their positions. As such, it is evident that the market sentiment is more bearish than bullish.

There appears to be an alignment between the negative funding rates and the sell pressure supplied by the $3.4 billion expired options and breach of the $91,000 Maximum Pain Point. GugaOnChain explains that such a correlation further strengthens the narrative that the Bitcoin market could see an additional significant drop in its price.

While the long-term market direction may be well-defined, its short-term sentiment, however, reflects a more modest stance of utmost caution.  As of press time, Bitcoin is valued at about $89,250. Over the past 24 hours, the premier cryptocurrency has lost approximately 3.38% of its value, per CoinMarketCap data.

BTC trading at $89,602 on the daily chart | Source: BTCUSDT chart on Tradingview.com
Featured image from Shutterstock, chart from Tradingview

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

contributor

Posted: December 7, 2025

Over the past day, pippin [PIPPIN] has rallied 59%, at press time, after weeks of quiet accumulation across the memecoin sector.

Its market cap jumped 33%, rising to $233.53 million from a low near $22 million on the 21st of November, breaking through previous ranges with steady momentum.

Traders are rotating back into mid‑caps, with PIPPIN delivering one of the strongest recoveries in the sector.

Source: TradingView

The daily timeframe confirms the shift, with the memecoin chart fully reclaiming long‑term resistance zones. Momentum candles now extend into levels not seen since earlier this year, giving the current rally significant weight.

Whales add $19M as retail volume jumps
According to data from BubbleMaps, 50 connected wallets bought $19 million in PIPPIN through synchronized entries.

HTX funded these addresses within narrow windows, received similar amounts of Solana [SOL], and showed almost no prior on-chain footprint. This pattern points to a coordinated buildup rather than isolated trading activity.

Source: Bubblemaps

On the 2nd of December, BubbleMaps flagged additional activity, revealing 26 addresses that withdrew 44% of all PIPPIN from Gate over the past two months, a total worth $96 million.

Source: Bubblemaps

Notably, most withdrawals hit on the 24th of October, the 23rd of November, and the majority came from newly funded wallets.

Heavy accumulation on centralized exchanges followed by structured withdrawals often signals strong conviction from well-capitalized players.

Decoding on-chain factors
CoinGlass data shows retail traders entering aggressively, with volume surging past $49 million and Open Interest (OI) rising over 38%, at press time, reinforcing each breakout attempt.

Meanwhile, market cap keeps climbing as liquidity deepens with every push.

Source: CoinGlass

Retail traders and whales are now moving in sync, turning the trend from a brief rebound into a more controlled advance. 

Buyers remain aggressive, with both spot and leveraged flows adding sustained pressure to the chart.

Final Thoughts

Whale accumulation and rising retail participation highlight strong conviction, reinforcing PIPPIN’s momentum across key resistance levels.
The question remains: Can the rally transform into a broader breakout, unlocking higher liquidity zones?

XRP trades around $2.04 and remains under pressure after weeks of volatile sentiment, marking a drop of 7.5% in the last 7 days and 9% in the last 30 days. The token dropped through parts of the last month, yet the network prepares for a technical shift that may shape long-term adoption. Smart Escrows now enter the ecosystem, and the upgrade unlocks programmable conditions inside the XRP Ledger’s native escrow system.

Vet, a well-known XRPL validator, shared the development on X. His update revealed a major step that turns basic escrows into programmable tools. The feature introduces on-ledger logic that evaluates preset conditions before funds move. This logic gives users a simple form of automation without a heavy smart-contract layer.

The Smart Escrow model stores a compact program inside each escrow object. The program checks conditions in real time and decides whether funds should release or return. Users no longer rely on outside systems to manage those conditions. XRPL keeps its fast settlement design while gaining expressive power.

How the New Conditional Logic WorksThe embedded logic checks on-chain data or oracle feeds during each evaluation. The process stays lightweight so the ledger maintains speed. Developers can automate basic agreements without building external apps or custom verification layers.

The design fits XRPL’s performance standards. Smart Escrows run programs that verify rules with minimal friction. A business can enforce milestones. A lender can trigger collateral release. A user can lock XRP until market prices meet the target. Each flow executes through rules set at creation.

Oracle Inputs Shape Real-World Use CasesOracles supply data such as exchange rates, delivery confirmations, or compliance checks. Smart Escrows use those inputs to determine outcomes. A price-based escrow triggers settlement when XRP hits the target. A vendor contract completes payment after an oracle confirms delivery. Institutions can create structured settlement paths across borders without custom code.

This upgrade offers new confidence for firms that rely on predictable execution. The XRPL community tests the amendment as validators move toward activation. Each validator prepares to run updated software so the feature launches cleanly.

Why Smart Escrows Matter for the XRPL EcosystemSmart Escrows strengthen automation without slowing the ledger. Users gain transparency because the conditions sit on-chain. Developers gain new flexibility. Institutions gain predictable behavior that fits regulated environments.

The feature expands XRPL’s reach in digital finance. It delivers logic that improves settlement, lending, vendor payments, and price-triggered flows. The XRPL moves from a simple escrow model to programmable conditional settlement.

Ripple Faces New Questions on Its Escrowed XRPThe conversation around Ripple’s escrowed holdings grows louder. Crypto Sensei sparked fresh debate when he described how Ripple can structure sales around escrowed XRP without releasing tokens into circulation. He noted that Ripple can sell rights to future escrow releases or even sell the destination accounts tied to those escrows. He stressed that such moves do not put XRP into the market until the escrow completes.

His comments challenged rumors that Ripple already sold large quantities to institutions. He argued that most claims lack proof because Ripple relocks about 700 million XRP each month. Those tokens would not return to escrow if Ripple no longer held control.

The Clarity Act Raises the StakesCrypto Sensei highlighted the Clarity Act, a proposed bill that limits any single company from holding more than 20% of a blockchain’s supply. Ripple controls about 45 billion XRP, equal to roughly 45% of the supply. If the bill becomes law, Ripple may need to reduce its holdings to around 20 billion XRP.

He outlined possible actions. Ripple may reveal who controls certain escrow accounts. It may create a clear plan to reduce its 45 billion XRP position. These steps matter because supply transparency shapes investor confidence.

What This Means for XRP’s OutlookXRP’s long-term trajectory depends on how Ripple manages future supply. Market participants monitor its escrow flows and institutional relationships. If Ripple sells rights tied to escrowed tokens, the buyer profile may influence market expectations.

Smart Escrows expand XRPL’s technical capabilities at the same moment Ripple faces new regulatory pressure. Both developments shape the next chapter for XRP. The network grows stronger while Ripple calculates how its holdings fit into a changing regulatory landscape.

Sat, 6/12/2025 - 20:00

Shiba Inu Layer-2 blockchain Shibarium has gained attention in the market as a popular SHIB explorer hints at an ongoing reset.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Shiba Inu Layer 2 Shibarium is under the spotlight as Shibariumscan, its dedicated blockchain explorer, hints at a reset. This speculation is not far fetched as the Shibarium network recently underwent a security upgrade, with its old public RPC connection retired.

Weeks back, the Shiba Inu team revealed an ongoing Shibarium RPC Migration Network upgrade, which included a legacy endpoint closure, with the old public RPC connection for Shibarium retired, thus ending access through the previous URL.

A look at the Shibariumscan explorer reveals something unusual: the numbers presently displayed are different from what one was previously used to.

HOT Stories

Before now, total blocks had crossed 14 million, while total transactions stood at above 1.56 billion, and total addresses above 272 million. At the moment, these figures are significantly lower.

The current count for total blocks is 2,378,324; total transactions is 168,046,095, while total addresses stood at 5,151,236. The daily transactions part of the page was also not found.

What happened?The drop in the Shibarium statistics might not be because activity necessarily slowed. A potential reason might be due to the Shibarium network retiring its old RPC. When an RPC endpoint is retired, explorers may rebuild or resync their data from a different index.

This might explain the drop in data reported, even though the chain is performing optimally. This premise is corroborated as Shibariumscan noted on its page an ongoing index to the chain, stating that the current counts might not be accurate.

A notice on the Shibariumscan page reads: "16% Blocks Indexed – We're indexing this chain right now. Some of the counts may be inaccurate."

In positive news, Shibarium’s utility layer is set for a major upgrade scheduled for Q2, 2026, amid efforts to provide full on-chain privacy for users.

Shiba Inu team member Lucie revealed a timeline of Q2, 2026, for Zama Shibarium privacy upgrade, allowing full on-chain privacy and confidential smart contracts on Shibarium and Bone thanks to Zama’s fully homomorphic encryption technology.

Related articles

The restaurant company's stock has brought all the trade-offs to the table you'd expect it to.

No one denies fast food restaurant chain McDonald's (MCD +0.87%) offers consumers an affordable eating experience. Sometimes, however, that's still not enough. As CEO Chris Kempczinski commented during November's third-quarter earnings conference call, "We continue to see a bifurcated consumer base with traffic from lower-income consumers declining nearly double digits in the third quarter." He reminded investors, "it's a trend that's persisted for nearly two years."

And this dynamic raises an important question for investors: How much have the money struggles being faced by a key segment of McDonald's customer base adversely impacted this company's stock?

Image source: Getty Images.

Answer: Not as much as you might think. Although it hasn't kept pace with the technology-led S&P 500 (^GSPC +0.19%) for the time frame (not that you would expect it to), over the course of the past five years, McDonald's stock has gained 46%. That number is ratcheted up to 63% when factoring in reinvested dividends during this stretch.

Today's Change

(

0.87

%) $

2.69

Current Price

$

311.23

Now take a closer look at the chart above. Yes, the broad market has outperformed McDonald's stock for the five years in question. Shares have made much more consistent forward progress, though, even performing well during 2022's bear market. Indeed, the fast-food restaurant chain's stock has frequently moved in opposition to the S&P 500's direction during this five-year stretch, confirming its categorization as a defensive holding.

Going forward, less performance but more predictability
That being said, know that prior to the beginning of the past five years, McDonald's stock consistently outperformed the S&P 500. Credit the fact that the company still had room to expand its physical footprint then, mostly. Now with 44,599 restaurants up and running worldwide, meaningful expansion opportunities are diminishing in number. From here, the bulk of the company's top- and bottom-line growth is going to come from higher prices and more foot traffic. This, of course, is easier said than done, as last quarter's U.S. same-store sales growth of 2.4% reminds us.

Nevertheless, a slower-growing McDonald's is still a reliably formidable one.

See, investing in this company isn't as much a bet on a restaurant chain as it is an investment in rental real estate. More than 95% of its stores are run by franchisees that pay ever-rising rent to operate from buildings owned by the company itself. The fact that McDonald's remains one of the world's most recognizable and marketable brand names is why these franchisees remain willing to agree to relatively unusual terms for the restaurant industry.

These terms are, of course, ideal for investors, in that these rent payments generate more reliable revenue, in turn supporting a dividend payment that's now been raised for 49 consecutive years.

It’s only been a day since Netflix announced an $82.7 billion deal to acquire Warner Bros., and the acquisition has already been described as sending Hollywood into “full-blown panic mode,” “possibly a death blow to theatrical filmmaking,” and maybe even “the end of Hollywood” itself.

Some of the firmest opposition has come from the Writers Guild of America, which issued a statement declaring, “This merger must be blocked.”

“The world’s largest streaming company swallowing one of its biggest competitors is what antitrust laws were designed to prevent,” the WGA said. “The outcome would eliminate jobs, push down wages, worsen conditions for all entertainment workers, raise prices for consumers, and reduce the volume and diversity of content for all viewers.”

While statements from other Hollywood unions were not quite as unequivocal, they still suggested that there are  “many serious questions” about the acquisition’s “impact on the future of the entertainment industry” (as the actors union SAG-AFTRA put it).

The deal came after a competitive process in which Paramount and Comcast also bids. Paramount was trying to acquire the entire company, while Netflix will only buy acquire the film and television studios, as well as the streaming business, after Warner Bros. moves forward with a plan to spin off its TV networks division.

Initially, Paramount was seen as the frontrunner, with its ties to the Trump administration (the studio is now run by David Ellison, son of Oracle co-founder and Trump ally Larry Ellison) easing the way for regulatory approval. But even before the Netflix deal was announced, Paramount’s lawyers sent an angry letter complaining about “a tilted and unfair process,” and Netflix soon emerged publicly as the winner.

This deal, which is expected to close in the third quarter of 2026, would presumably face significant regulatory scrutiny, and not just from Trump appointees. Senator Elizabeth Warren — a Democrat from Massachusetts and longtime critic of Big Tech — put out a statement of her own describing the deal as “an anti-monopoly nightmare.”

Techcrunch event

San Francisco
|
October 13-15, 2026

“A Netflix-Warner Bros. [merger] would create one massive media giant with control of close to half of the streaming market — threatening to force Americans into higher subscription prices and fewer choices over what and how they watch, while putting American workers at risk,” Warren said.

She also argued that antitrust enforcement — including the review process for this deal — must be conducted “fairly and transparently” rather than used to “invite influence-peddling and bribery.”

If the government ultimately blocks the acquisition, Netflix would be required to pay a $5.8 billion breakup fee. It’s not clear whether Warner Bros. would then continue operating as an independent company or would reconsider the previous acquisition offers.

Netflix held an analyst call to discuss the deal on Friday morning, and while many of the questions were focused on the financial impact on both companies, executives also attempted to address larger concerns.

For example, co-CEO Ted Sarandos said he’s “highly confident in the regulatory process.”

“This deal is pro-consumer, pro-innovation, pro-worker, it’s pro-creator, it’s pro-growth,” he added. “And our plans here are to work really closely with all the appropriate governments and regulators, but really confident that we’re going to get all the necessary approvals that we need.”

Sarandos also said that Netflix intends to keep HBO “operating largely as it is.” And although it’s not something Netflix has done in the past, Warner Bros. would also continue producing TV shows for other networks and streaming services, he said: “We want to keep that successful business operating.”

As for how HBO and HBO Max would be packaged with or folded into the Netflix app, co-CEO Greg Peters said it’s too early to get into specifics, but he said, “Needless to say, we think the HBO brand is very powerful for consumers. We think that the offering could constitute and would constitute a part of our plans and how we structure those for consumers.”

Beyond general concerns around consolidation, perhaps the biggest question is to what extent Netflix will support theatrical releases for the combined entity’s films — especially after Warner Bros. had a record-setting run of box office success this year, while Netflix’s theatrical releases only last for a couple weeks and skip major theatrical chains because of the limited exclusive window. (This was reportedly the deciding factor wjhen “Stranger Things” creators the Duffer Brothers signed an exclusive deal with Paramount.)

For his part, Sarandos said he “wouldn’t look at this as a change in approach for Netflix movies or for Warner movies for that matter,” and he noted that Netflix has released 30 movies in theaters this year (though again, usually on fewer screens and for a limited period of time).

Similarly, “everything that is planned on going to the theater through Warner Bros. will continue to go to the theaters through Warner Bros,” he said. But in the long term, he suggested that “the windows will evolve” so that movies come to streaming more quickly.

“My pushback has been mostly in the fact of the long exclusive windows, which we don’t really think of that consumer friendly,” he said.

December 06, 2025 1:51 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of James Hardie Industries plc (NYSE: JHX) between May 20, 2025 through August 18, 2025, both dates inclusive (the "Class Period") of the important December 23, 2025 lead plaintiff deadline.

SO WHAT: If you purchased James Hardie common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the James Hardie class action, go to https://rosenlegal.com/submit-form/?case_id=46976 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 23, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, James Hardie Industries plc misled investors about the strength of its key North America Fiber Cement segment between May 20 and August 18, 2025. Despite knowing by April and early May that distributors were destocking inventory, James Hardie falsely claimed demand remained strong and that stock levels were "normal." When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the James Hardie class action, go to https://rosenlegal.com/submit-form/?case_id=46976 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277128

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI® Translational analyses show stronger immune fitness and a more immunocompetent TME when CARVYKTI® is used earlier in the treatment journey Eighty percent of as-treated patients in CARTITUDE-4 with standard-risk cytogenetics remained progression-free and off treatment at 30 months after a single infusion of CARVYKTI® Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D demonstrate encouraging safety and efficacy in B-cell non-Hodgkin lymphoma
SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma (RRMM) patients. In triple-class-exposed patients who had received three prior lines of therapy, a median progression-free survival (mPFS) of 50.4 months was observed following a single infusion of CARVYKTI®. This represents one of the longest PFS outcomes reported for a BCMA-targeted CAR-T cell therapy in this heavily pretreated population.

These results, presented in an oral presentation (Abstract #92) at the 67th American Society of Hematology (ASH) Annual Meeting, add to a body of clinical evidence and real-world experience supporting the long-term benefits of CARVYKTI®, which has treated over 9,000 patients globally.

Building on these outcomes, findings from CARTITUDE-1 and CARTITUDE-4 demonstrated that patients treated earlier, after one or two prior lines of therapy, exhibited stronger immune fitness. These patients had higher baseline levels of CD4+ naïve T cells and a more immunocompetent tumor microenvironment (TME), biological features that suggest an association with longer PFS and consistent with the observation that mPFS had not been reached in as-treated CARTITUDE-4 patients at a median follow-up of 34 months.

“The translational analyses presented at ASH provide important insights into the biological basis of the durable responses we’re seeing clinically,” said Samir Parekh, M.D., Professor of Medicine, Hematology and Medical Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. “Patients who received CARVYKTI earlier showed more resilient immune systems and a more favorable TME, both of which are linked to improved progression-free survival. These data underscore the value of maintaining strong T-cell health to achieve sustained treatment benefit.” ‡

These findings further complement the robust clinical outcomes observed across the CARTITUDE program. In addition to these correlative analyses, the Company presented updated results from the Phase 3 CARTITUDE-4 study and first-in-human data from the dual-targeted allogeneic CAR-T candidate, LUCAR-G39D, in oral presentations at ASH.

Moreover, six poster presentations also provided subgroup durability data and real-world outcomes with CARVYKTI®, further reinforcing its potential across earlier lines of therapy.

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard risk relapsed / refractory multiple myeloma (Abstract #94)

The Phase 3 CARTITUDE-4 study evaluated CARVYKTI® versus standard therapies of pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) in adults with RRMM who had received one to three prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory agent (IMiD), and who were refractory to lenalidomide.

At a median follow-up of 33.6 months, intent-to-treat patients (N=208) with standard-risk cytogenetics in the CARVYKTI® arm (n=69) achieved a 30-month PFS rate of 71.0% (95% CI, 58.8–80.2) compared with 43.2% (95% CI, 31.3–54.5) in the standard-of-care arm (n=70). In the as-treated population (n=59), the 30-month PFS rate was 80.5% (95% CI, 67.2–88.8) for patients with standard-risk cytogenetics who received CARVYKTI® as study treatment.

Notably, all 26 patients who achieved minimal residual disease (MRD)-negative complete response at 12 months following CARVYKTI® infusion remained progression-free at 30 months.

“We are seeing deeper, more durable responses and long-term progression-free survival in patients with standard-risk disease, which underscores the value of early intervention with CAR-T therapy,” said Surbhi Sidana, M.D., Associate Professor of Medicine, Blood and Marrow Transplantation & Cellular Therapy at Stanford University School of Medicine.”‡

A phase 1 study of lucar-G39D: A novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell non-Hodgkin lymphoma (NHL) (Abstract #266)

Early Phase 1 results for LUCAR-G39D (NCT06395870) demonstrated a manageable safety profile and encouraging antitumor activity in adults with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

As of October 1, 2025, 16 patients were treated across five dose levels (DL) at a median follow-up of 6.1 months (range, 1.0 – 14.6). No dose-limiting toxicities, adverse event-related deaths, immune effector cell-associated neurotoxicity syndrome, tumor lysis syndrome, second primary malignancies, or graft-versus-host disease were reported. Serious adverse events occurred in 25% (4/16) of patients at DL4 and DL5. Cytokine release syndrome (CRS) occurred in 56.3% (9/16) of patients at DL2 to DL5, and all cases resolved. The overall response rate was 75% (12/16), including a complete response rate of 37.5% (6/16). The median time to best response was 2.9 months (range, 1.0 – 11.8), and 83.3% (10/12) of responders remained in remission at the time of data cut-off.

“The breadth of data presented at ASH highlights our continuous innovation in both commercial and next-generation CAR-T platforms,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “With a median progression-free survival of 50.4 months in triple-class-exposed patients with three prior lines of therapy, and even longer benefits seen with earlier use of CARVYKTI, our results demonstrate meaningful and durable responses. Our insights into immune-fitness, which emphasize that earlier intervention with CARVYKTI® drives deeper and lasting responses, as well as the encouraging preliminary data from our allogeneic program in B-cell non-Hodgkin lymphoma, support our vision for more effective, accessible cell therapies that improve patients’ lives.”

CARVYKTI® IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, PROLONGED and RECURRENT CYTOPENIA, and SECONDARY HEMATOLOGICAL MALIGNANCIESCytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with CARVYKTI®. Do not administer CARVYKTI® to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.

Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), which may be fatal or life-threatening, occurred following treatment with CARVYKTI®, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with CARVYKTI®. Provide supportive care and/or corticosteroids as needed.

Parkinsonism and Guillain-Barré syndrome (GBS) and their associated complications resulting in fatal or life-threatening reactions have occurred following treatment with CARVYKTI®.

Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®. HLH/MAS can occur with CRS or neurologic toxicities.

Prolonged and/or recurrent cytopenias with bleeding and infection and requirement for stem cell transplantation for hematopoietic recovery occurred following treatment with CARVYKTI®.

Immune Effector Cell-associated Enterocolitis (IEC-EC), including fatal or life-threatening reactions, occurred following treatment with CARVYKTI®.

Secondary hematological malignancies, including myelodysplastic syndrome and acute myeloid leukemia, have occurred in patients following treatment with CARVYKTI®. T-cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies, including CARVYKTI®.

WARNINGS AND PRECAUTIONS

INCREASED EARLY MORTALITY - In CARTITUDE-4, a (1:1) randomized controlled trial, there was a numerically higher percentage of early deaths in patients randomized to the CARVYKTI® treatment arm compared to the control arm. Among patients with deaths occurring within the first 10 months from randomization, a greater proportion (29/208; 14%) occurred in the CARVYKTI® arm compared to (25/211; 12%) in the control arm. Of the 29 deaths that occurred in the CARVYKTI® arm within the first 10 months of randomization, 10 deaths occurred prior to CARVYKTI® infusion, and 19 deaths occurred after CARVYKTI® infusion. Of the 10 deaths that occurred prior to CARVYKTI® infusion, all occurred due to disease progression, and none occurred due to adverse events. Of the 19 deaths that occurred after CARVYKTI® infusion, 3 occurred due to disease progression, and 16 occurred due to adverse events. The most common adverse events were due to infection (n=12).

CYTOKINE RELEASE SYNDROME (CRS), including fatal or life-threatening reactions, occurred following treatment with CARVYKTI®. Among patients receiving CARVYKTI® for RRMM in the CARTITUDE-1 & -4 studies (N=285), CRS occurred in 84% (238/285), including ≥ Grade 3 CRS (ASTCT 2019) in 4% (11/285) of patients. Median time to onset of CRS, any grade, was 7 days (range: 1 to 23 days). CRS resolved in 82% with a median duration of 4 days (range: 1 to 97 days). The most common manifestations of CRS in all patients combined (≥10%) included fever (84%), hypotension (29%) and aspartate aminotransferase increased (11%). Serious events that may be associated with CRS include pyrexia, hemophagocytic lymphohistiocytosis, respiratory failure, disseminated intravascular coagulation, capillary leak syndrome, and supraventricular and ventricular tachycardia. CRS occurred in 78% of patients in CARTITUDE-4 (3% Grade 3 to 4) and in 95% of patients in CARTITUDE-1 (4% Grade 3 to 4).

Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension. CRS has been reported to be associated with findings of HLH/MAS, and the physiology of the syndromes may overlap. HLH/MAS is a potentially life-threatening condition. In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS.

Confirm that a minimum of 2 doses of tocilizumab are available prior to infusion of CARVYKTI®.

Of the 285 patients who received CARVYKTI® in clinical trials, 53% (150/285) patients received tocilizumab; 35% (100/285) received a single dose, while 18% (50/285) received more than 1 dose of tocilizumab. Overall, 14% (39/285) of patients received at least 1 dose of corticosteroids for treatment of CRS.

Monitor patients at least daily for 7 days following CARVYKTI® infusion for signs and symptoms of CRS. Monitor patients for signs or symptoms of CRS for at least 2 weeks after infusion. At the first sign of CRS, immediately institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids.

Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time.

NEUROLOGIC TOXICITIES, which may be severe, life-threatening, or fatal, occurred following treatment with CARVYKTI®. Neurologic toxicities included ICANS, neurologic toxicity with signs and symptoms of Parkinsonism, GBS, immune mediated myelitis, peripheral neuropathies, and cranial nerve palsies. Counsel patients on the signs and symptoms of these neurologic toxicities, and on the delayed nature of onset of some of these toxicities. Instruct patients to seek immediate medical attention for further assessment and management if signs or symptoms of any of these neurologic toxicities occur at any time.

Among patients receiving CARVYKTI® in the CARTITUDE-1 & 4 studies for RRMM, one or more neurologic toxicities occurred in 24% (69/285), including ≥ Grade 3 cases in 7% (19/285) of patients. Median time to onset was 10 days (range: 1 to 101) with 63/69 (91%) of cases developing by 30 days. Neurologic toxicities resolved in 72% (50/69) of patients with a median duration to resolution of 23 days (range: 1 to 544). Of patients developing neurotoxicity, 96% (66/69) also developed CRS. Subtypes of neurologic toxicities included ICANS in 13%, peripheral neuropathy in 7%, cranial nerve palsy in 7%, parkinsonism in 3%, and immune mediated myelitis in 0.4% of the patients.

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Patients receiving CARVYKTI® may experience fatal or life-threatening ICANS following treatment with CARVYKTI®, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS.

Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, ICANS occurred in 13% (36/285), including Grade ≥3 in 2% (6/285) of the patients. Median time to onset of ICANS was 8 days (range: 1 to 28 days). ICANS resolved in 30 of 36 (83%) of patients, with a median time to resolution of 3 days (range: 1 to 143 days). Median duration of ICANS was 6 days (range: 1 to 1229 days) in all patients, including those with ongoing neurologic events at the time of death or data cutoff. Of patients with ICANS, 97% (35/36) had CRS. The onset of ICANS occurred during CRS in 69% of patients, before and after the onset of CRS in 14% of patients, respectively.

Immune Effector Cell-associated Neurotoxicity Syndrome occurred in 7% of patients in CARTITUDE-4 (0.5% Grade 3) and in 23% of patients in CARTITUDE-1 (3% Grade 3). The most frequent (≥2%) manifestations of ICANS included encephalopathy (12%), aphasia (4%), headache (3%), motor dysfunction (3%), ataxia (2%), and sleep disorder (2%).

Monitor patients at least daily for 7 days following CARVYKTI® infusion for signs and symptoms of ICANS. Rule out other causes of ICANS symptoms. Monitor patients for signs or symptoms of ICANS for at least 2 weeks after infusion and treat promptly. Neurologic toxicity should be managed with supportive care and/or corticosteroids as needed. Advise patients to avoid driving for at least 2 weeks following infusion.

Parkinsonism: Neurologic toxicity with parkinsonism has been reported in clinical trials of CARVYKTI®. Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, parkinsonism occurred in 3% (8/285), including Grade ≥3 in 2% (5/285) of the patients. Median time to onset of parkinsonism was 56 days (range: 14 to 914 days). Parkinsonism resolved in 1 of 8 (13%) of patients with a median time to resolution of 523 days. Median duration of parkinsonism was 243.5 days (range: 62 to 720 days) in all patients, including those with ongoing neurologic events at the time of death or data cutoff. The onset of parkinsonism occurred after CRS for all patients and after ICANS for 6 patients.

Parkinsonism occurred in 1% of patients in CARTITUDE-4 (no Grade 3 to 4) and in 6% of patients in CARTITUDE-1 (4% Grade 3 to 4).

Manifestations of parkinsonism included movement disorders, cognitive impairment, and personality changes. Monitor patients for signs and symptoms of parkinsonism that may be delayed in onset and managed with supportive care measures. There is limited efficacy information with medications used for the treatment of Parkinson’s disease for the improvement or resolution of parkinsonism symptoms following CARVYKTI® treatment.

Guillain-Barré Syndrome: A fatal outcome following GBS occurred following treatment with CARVYKTI® despite treatment with intravenous immunoglobulins. Symptoms reported include those consistent with Miller-Fisher variant of GBS, encephalopathy, motor weakness, speech disturbances, and polyradiculoneuritis.

Monitor for GBS. Evaluate patients presenting with peripheral neuropathy for GBS. Consider treatment of GBS with supportive care measures and in conjunction with immunoglobulins and plasma exchange, depending on severity of GBS.

Immune Mediated Myelitis: Grade 3 myelitis occurred 25 days following treatment with CARVYKTI® in CARTITUDE-4 in a patient who received CARVYKTI® as subsequent therapy. Symptoms reported included hypoesthesia of the lower extremities and the lower abdomen with impaired sphincter control. Symptoms improved with the use of corticosteroids and intravenous immune globulin. Myelitis was ongoing at the time of death from other cause.

Peripheral Neuropathy occurred following treatment with CARVYKTI®. Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, peripheral neuropathy occurred in 7% (21/285), including Grade ≥3 in 1% (3/285) of the patients. Median time to onset of peripheral neuropathy was 57 days (range: 1 to 914 days). Peripheral neuropathy resolved in 11 of 21 (52%) of patients with a median time to resolution of 58 days (range: 1 to 215 days). Median duration of peripheral neuropathy was 149.5 days (range: 1 to 692 days) in all patients, including those with ongoing neurologic events at the time of death or data cutoff.

Peripheral neuropathies occurred in 7% of patients in CARTITUDE-4 (0.5% Grade 3 to 4) and in 7% of patients in CARTITUDE-1 (2% Grade 3 to 4). Monitor patients for signs and symptoms of peripheral neuropathies. Patients who experience peripheral neuropathy may also experience cranial nerve palsies or GBS.

Cranial Nerve Palsies occurred following treatment with CARVYKTI®. Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, cranial nerve palsies occurred in 7% (19/285), including Grade ≥3 in 1% (1/285) of the patients. Median time to onset of cranial nerve palsies was 21 days (range: 17 to 101 days). Cranial nerve palsies resolved in 17 of 19 (89%) of patients with a median time to resolution of 66 days (range: 1 to 209 days). Median duration of cranial nerve palsies was 70 days (range: 1 to 262 days) in all patients, including those with ongoing neurologic events at the time of death or data cutoff. Cranial nerve palsies occurred in 9% of patients in CARTITUDE-4 (1% Grade 3 to 4) and in 3% of patients in CARTITUDE-1 (1% Grade 3 to 4).

The most frequent cranial nerve affected was the 7th cranial nerve. Additionally, cranial nerves III, V, and VI have been reported to be affected.

Monitor patients for signs and symptoms of cranial nerve palsies. Consider management with systemic corticosteroids, depending on the severity and progression of signs and symptoms.

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)/MACROPHAGE ACTIVATION SYNDROME (MAS): Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, HLH/MAS occurred in 1% (3/285) of patients. All events of HLH/MAS had onset within 99 days of receiving CARVYKTI®, with a median onset of 10 days (range: 8 to 99 days), and all occurred in the setting of ongoing or worsening CRS. The manifestations of HLH/MAS included hyperferritinemia, hypotension, hypoxia with diffuse alveolar damage, coagulopathy and hemorrhage, cytopenia, and multi-organ dysfunction, including renal dysfunction and respiratory failure.

Patients who develop HLH/MAS have an increased risk of severe bleeding. Monitor hematologic parameters in patients with HLH/MAS and transfuse per institutional guidelines. Fatal cases of HLH/MAS occurred following treatment with CARVYKTI®.

HLH is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of HLH/MAS should be administered per institutional standards.

PROLONGED AND RECURRENT CYTOPENIAS: Patients may exhibit prolonged and recurrent cytopenias following lymphodepleting chemotherapy and CARVYKTI® infusion.

Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, Grade 3 or higher cytopenias not resolved by Day 30 following CARVYKTI® infusion occurred in 62% (176/285) of the patients and included thrombocytopenia 33% (94/285), neutropenia 27% (76/285), lymphopenia 24% (67/285), and anemia 2% (6/285). After Day 60 following CARVYKTI® infusion, 22%, 20%, 5%, and 6% of patients had a recurrence of Grade 3 or 4 lymphopenia, neutropenia, thrombocytopenia, and anemia, respectively, after initial recovery of their Grade 3 or 4 cytopenia. Seventy-seven percent (219/285) of patients had one, two, or three or more recurrences of Grade 3 or 4 cytopenias after initial recovery of Grade 3 or 4 cytopenia. Sixteen and 25 patients had Grade 3 or 4 neutropenia and thrombocytopenia, respectively, at the time of death.

Monitor blood counts prior to and after CARVYKTI® infusion. Manage cytopenias with growth factors and blood product transfusion support according to local institutional guidelines.

INFECTIONS: CARVYKTI® should not be administered to patients with active infection or inflammatory disorders. Severe, life-threatening, or fatal infections occurred in patients after CARVYKTI® infusion.

Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, infections occurred in 57% (163/285), including Grade ≥3 in 24% (69/285) of patients. Grade 3 or 4 infections with an unspecified pathogen occurred in 12%, viral infections in 6%, bacterial infections in 5%, and fungal infections in 1% of patients. Overall, 5% (13/285) of patients had Grade 5 infections, 2.5% of which were due to COVID-19. Patients treated with CARVYKTI® had an increased rate of fatal COVID-19 infections compared to the standard therapy arm.

Monitor patients for signs and symptoms of infection before and after CARVYKTI® infusion and treat patients appropriately. Administer prophylactic, pre-emptive, and/or therapeutic antimicrobials according to the standard institutional guidelines. Febrile neutropenia was observed in 5% of patients after CARVYKTI® infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care, as medically indicated. Counsel patients on the importance of prevention measures. Follow institutional guidelines for the vaccination and management of immunocompromised patients with COVID-19.

Viral Reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients with hypogammaglobulinemia. Perform screening for Cytomegalovirus (CMV), HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) or any other infectious agents if clinically indicated in accordance with clinical guidelines before collection of cells for manufacturing. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines/clinical practice.

Reactivation of John Cunningham (JC) virus, leading to progressive multifocal leukoencephalopathy (PML), including cases with fatal outcomes, have been reported following treatment. Perform appropriate diagnostic evaluations in patients with neurological adverse events.

HYPOGAMMAGLOBULINEMIA: can occur in patients receiving treatment with CARVYKTI®. Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, hypogammaglobulinemia adverse event was reported in 36% (102/285) of patients; laboratory IgG levels fell below 500 mg/dL after infusion in 93% (265/285) of patients. Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion occurred in 94% (267/285) of patients treated. Fifty-six percent (161/285) of patients received intravenous immunoglobulin (IVIG) post CARVYKTI® for either an adverse reaction or prophylaxis.

Monitor immunoglobulin levels after treatment with CARVYKTI® and administer IVIG for IgG <400 mg/dL. Manage per local institutional guidelines, including infection precautions and antibiotic or antiviral prophylaxis.

Use of Live Vaccines: The safety of immunization with live viral vaccines during or following CARVYKTI® treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during CARVYKTI® treatment, and until immune recovery following treatment with CARVYKTI®.

HYPERSENSITIVITY REACTIONS occurred following treatment with CARVYKTI®. Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, hypersensitivity reactions occurred in 5% (13/285), all of which were ≤2 Grade. Manifestations of hypersensitivity reactions included flushing, chest discomfort, tachycardia, wheezing, tremor, burning sensation, non-cardiac chest pain, and pyrexia.

Serious hypersensitivity reactions, including anaphylaxis, may be due to the dimethyl sulfoxide (DMSO) in CARVYKTI®. Patients should be carefully monitored for 2 hours after infusion for signs and symptoms of severe reaction. Treat promptly and manage patients appropriately according to the severity of the hypersensitivity reaction.

IMMUNE EFFECTOR CELL-ASSOCIATED ENTERCOLITIS (IEC-EC) has occurred in patients treated with CARVYKTI®. Manifestations include severe or prolonged diarrhea, abdominal pain, and weight loss requiring parenteral nutrition. IEC-EC has been associated with fatal outcome from perforation or sepsis. Manage according to institutional guidelines, including referral to gastroenterology and infectious disease specialists.

In cases of refractory IEC-EC, consider additional workup to exclude alternative etiologies, including T-cell lymphoma of the GI tract, which has been reported in the post marketing setting.

SECONDARY MALIGNANCIES: Patients treated with CARVYKTI® may develop secondary malignancies. Among patients receiving CARVYKTI® in the CARTITUDE-1 & -4 studies, myeloid neoplasms occurred in 5% (13/285) of patients (9 cases of myelodysplastic syndrome, 3 cases of acute myeloid leukemia, and 1 case of myelodysplastic syndrome followed by acute myeloid leukemia). The median time to onset of myeloid neoplasms was 447 days (range: 56 to 870 days) after treatment with CARVYKTI®. Ten of these 13 patients died following the development of myeloid neoplasms; 2 of the 13 cases of myeloid neoplasm occurred after initiation of subsequent antimyeloma therapy. Cases of myelodysplastic syndrome and acute myeloid leukemia have also been reported in the post marketing setting. T-cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies, including CARVYKTI®. Mature T-cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusions, and may include fatal outcomes.

Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Janssen Biotech, Inc., at 1-800-526-7736 for reporting and to obtain instructions on collection of patient samples.

ADVERSE REACTIONS

The most common nonlaboratory adverse reactions (incidence greater than 20%) are pyrexia, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections-pathogen unspecified, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, and vomiting. The most common Grade 3 or 4 laboratory adverse reactions (incidence greater than or equal to 50%) include lymphopenia, neutropenia, white blood cell decreased, thrombocytopenia, and anemia.

Please read full Prescribing Information, including Boxed Warning, for CARVYKTI®.

ABOUT CARVYKTI® (CILTACABTAGENE AUTOLEUCEL; CILTA-CEL)

Ciltacabtagene autoleucel is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. The cilta-cel CAR protein features two BCMA-targeting single-domain antibodies designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells.i

In December 2017, Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize cilta-cel. In February 2022, cilta-cel was approved by the U.S. Food and Drug Administration (FDA) under the brand name CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma. In April 2024, cilta-cel was approved for the second-line treatment of patients with relapsed/refractory myeloma who have received at least one prior line of therapy, including a proteasome inhibitor, an immunomodulatory agent, and are refractory to lenalidomide.

In May 2022, the European Commission (EC) granted conditional marketing authorization of CARVYKTI® for the treatment of adults with relapsed and refractory multiple myeloma. In September 2022, Japan’s Ministry of Health, Labour and Welfare (MHLW) approved CARVYKTI®. Cilta-cel was granted Breakthrough Therapy Designation in the U.S. in December 2019 and in China in August 2020. In addition, cilta-cel received a PRIority MEdicines (PRIME) designation from the European Commission in April 2019. Cilta-cel also received Orphan Drug Designation from the U.S. FDA in February 2019, from the European Commission in February 2020, and from the Pharmaceuticals and Medicinal Devices Agency (PMDA) in Japan in June 2020. In March 2022, the European Medicines Agency’s Committee for Orphan Medicinal Products recommended by consensus that the orphan designation for cilta-cel be maintained on the basis of clinical data demonstrating improved and sustained complete response rates following treatment.
ABOUT CARTITUDE-4

CARTITUDE-4 (NCT04181827) is an ongoing, international, randomized, open-label Phase 3 study evaluating the efficacy and safety of cilta-cel versus pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy, including a PI and an IMiD.ii

ABOUT CARTITUDE-1

CARTITUDE-1 (NCT03548207) is a Phase 1b/2, open-label, multicenter study evaluating the safety and efficacy of cilta-cel in adults with relapsed and/or refractory with multiple myeloma who have received at least 3 prior lines of therapy or are double refractory to a PI and IMiD, received a PI, an IMiD, and anti-CD38 antibody and documented disease progression within 12 months of starting the most recent therapy. The primary objective of the Phase 1b portion of the study was to characterize the safety and confirm the recommended Phase 2 dose of cilta-cel, informed by the first-in-human study with LCAR-B38M CAR-T cells (LEGEND-2). The Phase 2 portion further evaluated the efficacy of cilta-cel with overall response rate as the primary endpoint.iii

ABOUT LUCAR-G39D

NCT06395870 is a Phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39D, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.iv

About MULTIPLE MYELOMA

Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells.v In 2024, it is estimated that more than 35,000 people will be diagnosed with multiple myeloma, and more than 12,000 people will die from the disease in the U.S.vi While some patients with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems, or infections.vii 

About Legend Biotech
With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Headquartered in the US, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at www.legendbiotech.com, and follow us on X (formerly Twitter) and LinkedIn.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: statements relating to Legend Biotech’s strategies and objectives; statements relating to CARVYKTI® and LUCAR-G39D, including Legend Biotech’s expectations for CARVYKTI®, LUCAR-G39D and their therapeutic potential; statements related to the potential results from ongoing studies in the CARTITUDE and LUCAR-G39D clinical development programs; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 11, 2025. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

‡ Samir Parekh, M.D., Professor of Medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, has provided consulting and advisory services to Legend Biotech; he has not been paid for any media work.

‡ Surbhi Sidana, M.D., Associate Professor of Medicine, Blood and Marrow Transplantation & Cellular Therapy at Stanford University School of Medicine, has provided consulting and advisory services to Legend Biotech; she has not been paid for any media work.

INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
[email protected]

PRESS CONTACT:
Alexandra Ventura
Tel: (732) 850-5598
[email protected]

i CARVYKTI™ Prescribing Information. Horsham, PA: Janssen Biotech, Inc.
ii ClinicalTrials.Gov. A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). https://www.clinicaltrials.gov/study/NCT04181827. Accessed March 2024.
iii ClinicalTrials.gov. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1). Available at: https://clinicaltrials.gov/ct2/show/NCT03548207 Accessed October 2022.
iv ClinicalTrials.gov. Targeting CD19/​CD20 Dual-targeted Cell in Patients With Relapsed/​Refractory B-cell Non-Hodgkin Lymphoma. Available at: https://clinicaltrials.gov/study/NCT06395870  Accessed November 2024.
v American Cancer Society. ”What is Multiple Myeloma?”. Available at: https://www.cancer.org/cancer/types/multiple-myeloma/about/what-is-multiple-myeloma.html. Accessed March 2024.
vi American Cancer Society. “Key Statistics About Multiple Myeloma.” Available at: https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html. Accessed March 2024
vii American Cancer Society. Multiple myeloma: early detection, diagnosis, and staging. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8740.00.pdf. Accessed March 2023.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data are being presented during an oral presentation at the 67th American Society o.

Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF) CEO Ralph Rushton talked with Proactive about the company’s recent infill drilling program at its Berenguela silver-copper-manganese project in southern Peru, located near the town of Santa Lucia.

The program aimed to upgrade inferred resources to the measured and indicated category.

The drilling targeted four to five different areas, including clusters near the edges of the mineralized system and areas known to contain high copper intercepts on the eastern side.

The project benefits from strong infrastructure access, including road, rail, and power, and the mineralization is at surface, making it potentially open-pittable.

Rushton noted that the results of the drilling have been positive, supporting confidence in the project's continued development.

Proactive: All right. Welcome back inside our Proactive newsroom. And joining me now is Ralph Rushton. He is the CEO of Aftermath Silver. Ralph, good to see you again. How are you?

Ralph Rushton: I'm very well, thank you. How are you?

Good, good, good. So I know that the company is out with some significant news and updates on your resource. Tell us a little bit about the project itself and some of the work that's gone into this.

Yeah, the project is a silver-copper-manganese system in southern Peru near the town of Santa Lucia. It has all the infrastructure we need — road, rail, and power. It's at surface, so it's potentially open-pittable. So it’s a very interesting mineralized system. What we've been doing recently is infill drilling, earlier this year, with the objective of converting inferred resources into measured and indicated. And we've successfully done that, registering about a 28% increase in measured and indicated tonnes.

And this is only on one small portion of the property, correct?

Yeah. We had four or five different areas that we drilled. We had a few little clusters of holes within the system, a few around the edges of the mineralization, and a couple over to the eastern side of it, where we know we have some very high copper intercepts. So there was a variety of different objectives with the program, and all of it was carried off very successfully.

So you mentioned the next steps, now that you’ve done this particular work. There’s still a lot of work ahead here in 2026?

There is. The next step for us is shifting into a much more detailed engineering study. So we are actively considering that at the moment. We’ll be talking to engineering groups and looking for proposals on actually moving probably to a more detailed study — a PEA, perhaps along the lines of a PFS, a pre-feasibility study.

But after seeing what you've seen and the work that you've done, you're still pretty confident this is going to be a really good project moving forward?

Yeah, absolutely. And given the commodity price environment at the moment — silver was nearly at $60 this morning — it's all looking... the stars are aligned at the moment for that one.

Quotes have been lightly edited for style and clarity

Buying the right dividend stocks in December can set your portfolio up for 2026 gains.

You shouldn't buy a dividend stock just for its yield, but some companies combine attractive payouts with long-term tailwinds. One of the companies on this list will likely reach a $1 trillion valuation in 2026, while the other may achieve the same feat by 2030.

Strong revenue growth and long-term catalysts are two core themes for these stocks, but investors are more excited about what these stocks will turn into over the next five years. They are two of the best dividend stocks to buy in December.

Walmart is heading to a $1 trillion market cap

Image source: Getty Images.

Walmart (WMT +0.29%) is the world's largest retailer, and that comes with significant scaling and pricing advantages. Each store becomes the go-to place for groceries, toys, school supplies, and everything in between.

While some investors worried that Amazon (AMZN +0.18%) would hurt Walmart, the global retailer is making significant gains in e-commerce. The company's e-commerce segment grew by 27% year-over-year in the recent quarter,  with its physical locations continuing to play a major role.

Each Walmart store acts as a storage facility for e-commerce orders. Customers can pick up items from the store or have them delivered. Walmart's vast retail footprint is a significant advantage for its e-commerce operations, with one location within 10 miles of 90% of the U.S. population. This proximity makes Walmart one of the most convenient and affordable e-commerce options.

Today's Change

(

0.29

%) $

0.34

Current Price

$

115.17

Walmart doesn't have as many revenue streams as Amazon. It doesn't have cloud computing, streaming, or AI chips, but Walmart is growing its ad segment, which is critical for profit margin expansion. The retailer's global advertising sales surged by 53% year-over-year in the recent quarter.

Advertising is still a small part of the overall business, but Walmart's profit margins should surge as this segment grows. Walmart stock recently passed a $900 billion market cap, giving it a realistic shot of becoming a $1 trillion company in 2026, as that's an 11% jump.

Qualcomm's AI chips make the stock look like a bargain
Qualcomm (QCOM +0.26%) investors have watched other semiconductor stocks ride the AI wave. A five-year return just above 10% doesn't sound exciting when looking at stocks like Nvidia (NVDA 0.56%) and Advanced Micro Devices (AMD +0.92%).

Today's Change

(

0.26

%) $

0.46

Current Price

$

174.81

However, Qualcomm may soon have its time in the sun, much to the delight of patient investors. The company announced that it is working on its own AI chips, which can compete with Nvidia and AMD chips. AI chips are the hottest semiconductors right now, and Qualcomm's entry into the market can result in billions of additional dollars every quarter.

Qualcomm's AI200 chips are scheduled to go on sale in 2026, while its AI250 chips will be available in 2027. Tech giants have already shown a willingness to use AI chips from other brands instead of relying exclusively on Nvidia, so that bodes well for Qualcomm.

The release windows of Qualcomm's AI chips and parabolic spending in the industry suggest material financial gains are possible in 2026. The stock isn't pricing in that scenario yet, and it currently offers a 2% yield. That type of yield is hard to find for AI chipmakers, and chances are Qualcomm's yield won't be this high for long.

Qualcomm might be one of the last chances to get a high-yield AI growth stock. The tech giant has been producing chips for decades, and it's easy to see the company penetrating part of the AI chip market once its chips are available.

The chipmaker is still achieving respectable growth rates without AI chips. Revenue increased by 10% year-over-year in the fourth quarter of its fiscal 2025, with fiscal 2025 revenue as a whole up by 14% year-over-year. That's a good baseline leading into the launch of Qualcomm's AI chips.

Qualcomm's market cap is approaching $200 billion. If it becomes yet another AI chipmaker with a $1 trillion valuation -- and I think it could in the coming years -- the current price represents an opportunity.

Altria has a lofty 7.2% dividend yield, but the business backing the dividend may not be as reliable as you hope.

If you don't look under the hood, Altria (MO 0.60%) appears to be a very compelling investment. It operates in the consumer staples sector, it has a very large 7.2% yield, and the dividend has been increased regularly for years.

Before you jump on the stock, thinking you've set yourself up for a lifetime of reliable dividend income, lift up the covers and take a closer look at the business that backs the dividend.

Here's why you might not like what you see.

Image source: Getty Images.

Not your typical consumer staple item
Consumer staples companies produce products that are purchased regularly, regardless of the market or economic environment, and typically have a modest cost. Brand loyalty is often a significant factor in this space as well. All these factors work in favor of Altria's most important offering: Smokable tobacco products, such as cigarettes. Taken as a group, smokeable tobacco accounts for a huge 88% of the company's top line.

Most consumer staples products are necessity items, like food, toilet paper, and toothpaste. You most certainly need to buy these items regularly. Tobacco isn't a necessity. It is a consumer staple largely because of the addictive nature of nicotine, which keeps buyers coming back for more. Unlike makers of deodorant and similar products, tobacco stocks are really sin stocks. That's important because Altria's smokable products group has been in decline for years as cigarette smoking has increasingly fallen out of favor with consumers.

In the third quarter of 2025, volume in the business dropped 8%. Through the first nine months of the year, volume was off by 10.3%. In 2024, volumes declined 10%. In 2023, volumes fell 9.6%. That is a terrible trend that should be a warning sign to anyone who owns or is thinking about owning tobacco-focused Altria. Most investors would be running for the hills if this were a company that produced food.

The numbers add up, but only because of Altria's buybacks
Given that backdrop, it should come as little surprise that the top line of Altria's income statement fell 3% in Q3 2025, while it was down roughly 3.4% through the first nine months of the year. What might be confusing is that the company's adjusted earnings rose 3.6% and 5.9%, respectively, over those same time periods.

There are two things to monitor here. First, the volume decline didn't lead to as material a revenue decline as you might expect. That's because the addictive nature of nicotine has allowed Altria and its peers to jack up the price of their smokes on a regular basis. For a long time, the additional revenue from price hikes more than offset the effect from volume declines, but that is now ancient history. Price hikes now appear to be a part of the volume problem.

Today's Change

(

-0.60

%) $

-0.35

Current Price

$

57.99

The second issue to consider is earnings, which rose despite the drop on the top line. That was largely thanks to the company's stock buybacks. In Q3 2025, Altria repurchased 1.9 million shares, bringing the total to 12.3 million shares over the first nine months of the year. Year over year, the company's share count fell 1.4% in Q3 and 2.4% through the first three quarters.

To be fair, the company's cost-cutting efforts have also helped support the bottom line. However, the big-picture story remains the same. Altria's most significant business is under severe pressure, which is having an increasingly negative effect on the company's financial results. Since the volume decline in smokable products is unlikely to change direction, buying Altria is, effectively, buying a business that's in decline.

The future could be brighter than it seems today
Despite a lofty yield and strong dividend history, most conservative dividend investors will probably be better off avoiding Altria. In fact, if you buy Altria, you are really betting that management can milk the dying smokable tobacco business long enough to fund the buildout of divisions capable of offsetting the ongoing declines.

That might happen, but so far, Altria's efforts have been less than impressive, with failed efforts in vaping and marijuana that cost investors billions in write-offs. The risk-reward balance for this high-yield stock is currently tilted in the wrong direction for long-term investors.

December 06, 2025 2:25 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CarMax, Inc. (NYSE: KMX) between June 20, 2025 and November 5, 2025, both dates inclusive (the "Class Period") of the important January 2, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased CarMax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the CarMax class action, go to https://rosenlegal.com/submit-form/?case_id=47077 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner 90Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated CarMax's growth prospects when, in reality, its earlier growth in the 2026 fiscal year was a temporary benefit from customers buying cars due to speculation regarding tariffs; and (2) as a result, defendants' statements about CarMax's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the CarMax class action, go to https://rosenlegal.com/submit-form/?case_id=47077 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277103

2025 was a tough year for this Vegas-focused gaming operator, but better times may lie ahead for "the house" in 2026.

Chances are you are aware of the "Vegas is dead" meme that has been widespread in media headlines throughout this year. This phenomenon, describing decreased tourism to what's known as Sin City, especially had an impact on gaming companies focused on the resort destination, such as Caesars Entertainment (CZR +1.31%).

Decreased visits to Vegas affected not just Caesars' bottom line; it had an even stronger impact on investor perceptions about the company's future. At least, that's the takeaway after the stock's nearly 30% drop since the start of the year.

However, as of late, Caesars' shares have been bouncing back on the heels of promising gaming revenue data. While a return to the stock's post-pandemic high-water mark may not be in the cards, this stock may have the potential to make a major comeback in the year ahead.

Image source: Getty Images.

Vegas slump counters other positives for Caesars in 2025
Whether you blame it on international tourists protesting the recent tariff hikes, or on American tourists shunning it for its high prices and perceived lack of value for money, the figures do not lie: So far in 2025, Las Vegas has attracted fewer visitors than it did in 2024.

Per the latest data from the Las Vegas Convention and Visitors Authority (LVCVA), during the 10-month period ending October 2024, visitor volume was down 7.6%, while convention attendance was down 0.6%, and revenue per available room (RevPAR) down by 8.7%.

Today's Change

(

1.31

%) $

0.30

Current Price

$

23.24

Again, this was especially bad news for Caesars, which operates not just Caesars Palace in Las Vegas, but several other large casino resorts in the gaming destination. Around a third of the company's overall revenue comes from these Las Vegas properties. Worse yet, as seen last quarter, these properties experienced an even greater drop in revenue and profitability than you might think after first hearing the LVCVA figures.

During the nine months ending Sept. 30, 2025, Caesars' Las Vegas properties reported a 5.1% year-over-year (YoY) drop in revenue. Stronger results from its regional casinos and online gaming businesses help to make up for this top-line drop, but overall adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) for the company was down 4.2% during this time frame, with net losses increasing 16.6%, from $252 million to $289 million.

Keep an eye out for these two catalysts going into 2026
While the company may have experienced tough times in 2025, the coming year could prove much stronger for Caesars. After all, in October, the Las Vegas Strip's gross gaming revenue was up 8% from the prior year's month.

Only time will tell, but this could foreshadow stronger results in the quarters ahead. Outside a Las Vegas rebound, Caesars Entertainment may have another potential catalyst on its hands, with its digital segment. As Texas Capital analyst David Bain argued back in December, proceeds from an IPO of the gaming unit could generate billions in new capital that Caesars could use to pay down debt. A spinoff of the remaining interest could unlock tremendous value.

Regarding the performance of Caesars' shares in 2026, all bets are off. Continued macroeconomic uncertainties persist, clouding the near-term outlook. Still, while likely best to stay out of action with Caesars' shares right now, keep an eye out for these potential catalysts.